EODData

MEMBERSHIP REGISTER LOG IN

FRA, S09: Sutro Biopharma Inc

05 Nov 2025
LAST:

0.8925

CHANGE:
 0.03		OPEN:
0.8710		HIGH:
0.8925		ASK:
0.0000		VOLUME:
5.0K
CHG(%):
2.94		PREV:
0.9195		LOW:
0.8710		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 250.87100.89250.87100.89255.0K
04 Nov 250.92850.92900.91950.91955.0K
03 Nov 250.95100.95300.95000.95005.0K
31 Oct 250.99600.99600.95700.95705.0K
30 Oct 250.88200.88200.86750.87755.0K
29 Oct 250.92200.92650.86450.87355.0K
28 Oct 250.97450.97450.92200.92205.0K
27 Oct 250.89150.90900.85700.85705.0K
24 Oct 250.88550.89750.88300.89755.0K
23 Oct 250.97000.97000.96400.96405.0K

COMPANY PROFILE

Name:Sutro Biopharma Inc
About:Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Website:https://www.sutrobio.com
ISIN:US8693671021
LEI:5493005U6P15VD25P851

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.31 
Forward P/E:-0.34 
PEG Ratio:0.00 
Price to Sales:0.76 
Price to Book:-2.42 
Profit Margin:-2.00 
Operating Margin:0.24 
Return on Assets:-0.28 
Return on Equity:-3.48 
Revenue:90.67M 
Shares:84.77M 
Market Cap:75.66M 

TECHNICAL INDICATORS

MA5:0.923.0%
MA10:0.912.1%
MA20:0.855.4%
MA50:0.7913.3%
MA100:0.7322.2%
MA200:0.872.7%
STO9:25.54
STO14:44.15
RSI14:64.26 
WPR14:-52.04
MTM14:0.10
ROC14:0.13 
ATR:0.07 
Week High:1.0011.6%
Week Low:0.863.2%
Month High:1.0214.2%
Month Low:0.662.7%
Year High:4.03351.8%
Year Low:0.4692.3%